Limits...
Clinical characteristics of XP11.2 translocation/TFE3 gene fusion renal cell carcinoma: a systematic review and meta-analysis of observational studies.

Cheng X, Gan W, Zhang G, Li X, Guo H - BMC Urol (2016)

Bottom Line: Survival curves presented comparable outcomes between male and female (P = 0.707) as well as between children and adults (P = 0.383).Female patients with Xp11.2 RCC in adults exhibit a high incidence compared to male, but not in children.Comparable clinical characteristics including incidence of distant and lymphatic metastases, tumor stage and prognosis is presented between male and female as well as between children and adults.

View Article: PubMed Central - PubMed

Affiliation: Department of Urology, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, No. 321 Zhongshan Road, Nanjing, 210008, Jiangsu Province, China.

ABSTRACT

Background: Renal cell carcinoma (RCC) associated with Xp11.2 translocation/TFE3 gene fusion (Xp11.2 RCC) is a rare subtype of RCC which is firstly described as a distinct entity in 2004 so that clinical characteristics of Xp11.2 RCC in different gender and age are unknown. The purpose of systematic review and meta-analysis is to provide a comprehensive assessment on them.

Methods: MEDLINE, EMBASE and Cochrane databases were searched for studies which evaluate the clinical characteristics of Xp11.2 RCC. The literature published between July 2004 and May 2014 was searched.

Results: A total of 15 studies with 147 participants were included. The meta-analysis demonstrated that number of patients of all age in female was higher than in male with pooled OR of 3.93(95 % CI = 1.66-9.34). However, incidence of distant metastases (OR = 0.34, 95 % CI = 0.12-1.57) and lymphatic metastases (OR = 0.51, 95 % CI = 0.14-1.91), tumor stage (OR = 0.85, 95 % CI = 0.34-2.15) and overall survival (OS) (OR = 0.46, 95 % CI = 0.05-4.34) between male and female were comparable. Incidence in female was higher than in male with pooled OR of 5.13(95 % CI = 1.67-15.72) in adults, while in children no gender-related predominance (OR = 1.19, 95 % CI = 0.38-3.72) was observed. In addition, incidence of distant metastases (OR = 1.00, 95 % CI = 0.13-7.84) and lymphatic metastases (OR = 1.00, 95 % CI = 0.07-13.67) and tumor stage (OR = 1.94, 95 % CI = 0.20-19.03) between children and adults were comparable. Survival curves presented comparable outcomes between male and female (P = 0.707) as well as between children and adults (P = 0.383).

Conclusions: Female patients with Xp11.2 RCC in adults exhibit a high incidence compared to male, but not in children. Comparable clinical characteristics including incidence of distant and lymphatic metastases, tumor stage and prognosis is presented between male and female as well as between children and adults.

No MeSH data available.


Related in: MedlinePlus

The survival function of patients. a Overall survival curve between male and female. b Overall survival curve between children and adult
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4940698&req=5

Fig5: The survival function of patients. a Overall survival curve between male and female. b Overall survival curve between children and adult

Mentions: Totally, the number of included patients was 147 (n = 98 for women and n = 49 for men). We observed that I2 value was > 50 % in the group of incidence of patients of all age in different gender (I2 statistic = 55 %, P = 0.005). Therefore we applied random- effect model in meta-analysis of this data. Meanwhile, no evidence for significant publication bias was observed in this pooled group. For other group, there was no evidence for heterogeneity about incidence of distant (I2 statistic = 0 %, P = 0.81) and lymphatic metastases (I2 statistic = 0 %, P = 0.83), tumor stage (I2 statistic = 0 %, P = 0.57) and OS (I2 statistic = 0 %, P = 0.51). Results of meta-analysis demonstrated that the incidence of Xp11.2 in female was significantly higher than in male with pooled OR of 3.93(95 % CI = 1.66–9.34). However, incidence of distant metastases (OR = 0.43, 95 % CI = 0.12–1.57) and lymphatic metastases (OR = 0.51, 95 % CI = 0.14–1.91, tumor stage (OR = 0.85, 95 % CI = 0.34–2.15) and overall survival (OS) (OR = 0.46, 95 % CI = 0.05–4.34) between male and female were comparable. The result of OS consistent with analysis for clinical characteristics of Xp11.2 RCC was confirmed by survival function (P = 0.707), as shown in Fig. 5a.Fig. 5


Clinical characteristics of XP11.2 translocation/TFE3 gene fusion renal cell carcinoma: a systematic review and meta-analysis of observational studies.

Cheng X, Gan W, Zhang G, Li X, Guo H - BMC Urol (2016)

The survival function of patients. a Overall survival curve between male and female. b Overall survival curve between children and adult
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4940698&req=5

Fig5: The survival function of patients. a Overall survival curve between male and female. b Overall survival curve between children and adult
Mentions: Totally, the number of included patients was 147 (n = 98 for women and n = 49 for men). We observed that I2 value was > 50 % in the group of incidence of patients of all age in different gender (I2 statistic = 55 %, P = 0.005). Therefore we applied random- effect model in meta-analysis of this data. Meanwhile, no evidence for significant publication bias was observed in this pooled group. For other group, there was no evidence for heterogeneity about incidence of distant (I2 statistic = 0 %, P = 0.81) and lymphatic metastases (I2 statistic = 0 %, P = 0.83), tumor stage (I2 statistic = 0 %, P = 0.57) and OS (I2 statistic = 0 %, P = 0.51). Results of meta-analysis demonstrated that the incidence of Xp11.2 in female was significantly higher than in male with pooled OR of 3.93(95 % CI = 1.66–9.34). However, incidence of distant metastases (OR = 0.43, 95 % CI = 0.12–1.57) and lymphatic metastases (OR = 0.51, 95 % CI = 0.14–1.91, tumor stage (OR = 0.85, 95 % CI = 0.34–2.15) and overall survival (OS) (OR = 0.46, 95 % CI = 0.05–4.34) between male and female were comparable. The result of OS consistent with analysis for clinical characteristics of Xp11.2 RCC was confirmed by survival function (P = 0.707), as shown in Fig. 5a.Fig. 5

Bottom Line: Survival curves presented comparable outcomes between male and female (P = 0.707) as well as between children and adults (P = 0.383).Female patients with Xp11.2 RCC in adults exhibit a high incidence compared to male, but not in children.Comparable clinical characteristics including incidence of distant and lymphatic metastases, tumor stage and prognosis is presented between male and female as well as between children and adults.

View Article: PubMed Central - PubMed

Affiliation: Department of Urology, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, No. 321 Zhongshan Road, Nanjing, 210008, Jiangsu Province, China.

ABSTRACT

Background: Renal cell carcinoma (RCC) associated with Xp11.2 translocation/TFE3 gene fusion (Xp11.2 RCC) is a rare subtype of RCC which is firstly described as a distinct entity in 2004 so that clinical characteristics of Xp11.2 RCC in different gender and age are unknown. The purpose of systematic review and meta-analysis is to provide a comprehensive assessment on them.

Methods: MEDLINE, EMBASE and Cochrane databases were searched for studies which evaluate the clinical characteristics of Xp11.2 RCC. The literature published between July 2004 and May 2014 was searched.

Results: A total of 15 studies with 147 participants were included. The meta-analysis demonstrated that number of patients of all age in female was higher than in male with pooled OR of 3.93(95 % CI = 1.66-9.34). However, incidence of distant metastases (OR = 0.34, 95 % CI = 0.12-1.57) and lymphatic metastases (OR = 0.51, 95 % CI = 0.14-1.91), tumor stage (OR = 0.85, 95 % CI = 0.34-2.15) and overall survival (OS) (OR = 0.46, 95 % CI = 0.05-4.34) between male and female were comparable. Incidence in female was higher than in male with pooled OR of 5.13(95 % CI = 1.67-15.72) in adults, while in children no gender-related predominance (OR = 1.19, 95 % CI = 0.38-3.72) was observed. In addition, incidence of distant metastases (OR = 1.00, 95 % CI = 0.13-7.84) and lymphatic metastases (OR = 1.00, 95 % CI = 0.07-13.67) and tumor stage (OR = 1.94, 95 % CI = 0.20-19.03) between children and adults were comparable. Survival curves presented comparable outcomes between male and female (P = 0.707) as well as between children and adults (P = 0.383).

Conclusions: Female patients with Xp11.2 RCC in adults exhibit a high incidence compared to male, but not in children. Comparable clinical characteristics including incidence of distant and lymphatic metastases, tumor stage and prognosis is presented between male and female as well as between children and adults.

No MeSH data available.


Related in: MedlinePlus